Evolution, progress, and prospects of research on transjugular intrahepatic portosystemic shunt applications

Wang, Peng; Qi, Xun; Xu, Ke

doi:10.1016/j.jimed.2021.02.001

Cited by 3 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was traditionally used in portal hypertension and variceal bleeding, but the efficacy in BCS is now well documented, with reported 93% procedural success and 84% 5-year liver transplant–free survival. 12 , 13 TIPS in BCS is recommended to prevent hepatic congestion from leading to cirrhosis; in pre-existing liver cirrhosis and portal hypertension; and extensive hepatic vein occlusion. Complications of the procedure include bleeding, stent thrombosis or dysfunction, and hepatic encephalopathy.…”

Section: Discussionmentioning

confidence: 99%

Budd-Chiari syndrome and extensive inferior vena cava thrombosis treated with sequential interventional radiology and transjugular intrahepatic portosystemic shunting: A case report from Kenya

Kuka

Nduati

Mwirigi

et al. 2023

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

Budd-Chiari syndrome is a rare disease characterized by the obstruction of hepatic venous outflow. Stepwise treatment options aimed to relieve obstruction and prevent complications of Budd-Chiari syndrome are medical therapy, interventional recanalization, and surgery. Aggressive interventions for complicated Budd-Chiari syndrome are placement of a transjugular intrahepatic portosystemic shunt, surgical shunting, or liver transplantation. Although literature suggests differences in the presentation and management between Europe and Asia, cases documenting successful use of stepwise management of Budd-Chiari syndrome in Sub-Saharan Africa are scarce. A 47-year-old male on treatment for chronic hepatitis B presented with abdominal pain and distension for 2 weeks and findings of gross ascites without stigmata of chronic liver disease. Laboratory investigations performed showed anemia, elevated transaminases, coagulopathy, and renal dysfunction. Abdominal ultrasound and computed tomography abdominal scan revealed filling defects in intrahepatic veins and inferior vena cava extending to bilateral renal and external iliac veins. Extensive workup for thrombophilia and myeloproliferative disorders was negative. The diagnosis was hepatic dysfunction secondary to inferior vena cava obstruction due to a thrombus in the setting of extensive inferior vena cava thrombosis, and heparin was initiated. However, due to lack of recanalization with anticoagulation, we performed aspiration thrombectomy, balloon angioplasty, and local thrombolysis. Transjugular intrahepatic portosystemic shunt procedure was subsequently done due to hepatic venous congestion and refractory ascites. He was discharged on oral anticoagulation. Imaging exams performed 4 months later showed patent inferior vena cava and transjugular intrahepatic portosystemic shunt, good flows in the portal vein and resolution of ascites.

show abstract

Section: Discussionmentioning

confidence: 99%

Budd-Chiari syndrome and extensive inferior vena cava thrombosis treated with sequential interventional radiology and transjugular intrahepatic portosystemic shunting: A case report from Kenya

Kuka

Nduati

Mwirigi

et al. 2023

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

show abstract

“… 5 CTPV was previously considered a contraindication for transjugular intrahepatic portosystemic shunt (TIPS); however, recent studies demonstrated the effectiveness of TIPS for CTPV. 6 , 7 , 8 Chen et al. reported a success rate of 77.8%, 9 while Luo et al.…”

Section: Introductionmentioning

confidence: 98%

Application of transmesenteric vein extrahepatic portosystemic shunt in treatment of symptomatic portal hypertension with cavernous transformation of portal vein

Cui

et al. 2023

Journal of Interventional Medicine

View full text Add to dashboard Cite

Transjugular intrahepatic portosystemic shunting in patients over 60 years with cirrhosis and comorbidities when liver transplantation is reasonably denied

Korobka,

Khoronko,

Korobka

et al. 2024

Ann. hir. gepatol.

View full text Add to dashboard Cite

Aim. To determine the potential of TIPS that provides effective portal decompression for longevity and quality of life of patients over 60 years with cirrhosis and concomitant pathology when liver transplantation is reasonably denied.Materials and methods. The study included 27 patients aged over 60 with comorbidities, who underwent TIPS in 2016–2023 due to life-threatening manifestations of complicated portal hypertension of cirrhotic origin.Results. TIPS provided effective portal decompression in all 27 patients, confirmed by a 55.4 ± 5.2% reduction in portal pressure gradient. No hospital and 6-week mortality was recorded. 2 deaths (7.4%) were registered within one year after shunt surgery.Conclusion. In addition to lessening the risk of life-threatening complications, reduction of portal hypertension in liver cirrhosis provides favorable conditions for therapy of concomitant diseases, limited by concerns regarding hepatic decompensation. Due to the achieved stabilization of comorbidities, the denial to include the patient in the waiting list for liver transplantation can be reconsidered.

show abstract

Evolution, progress, and prospects of research on transjugular intrahepatic portosystemic shunt applications

Cited by 3 publications

References 35 publications

Budd-Chiari syndrome and extensive inferior vena cava thrombosis treated with sequential interventional radiology and transjugular intrahepatic portosystemic shunting: A case report from Kenya

Budd-Chiari syndrome and extensive inferior vena cava thrombosis treated with sequential interventional radiology and transjugular intrahepatic portosystemic shunting: A case report from Kenya

Application of transmesenteric vein extrahepatic portosystemic shunt in treatment of symptomatic portal hypertension with cavernous transformation of portal vein

Transjugular intrahepatic portosystemic shunting in patients over 60 years with cirrhosis and comorbidities when liver transplantation is reasonably denied

Contact Info

Product

Resources

About